Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Express Scripts Purchase Deal For NextRx Includes 10-Year PBM Contract With WellPoint

This article was originally published in The Pink Sheet Daily

Executive Summary

With the acquisition of the largest plan-owned pharmacy benefit manager, Express Scripts will move to second place among the big stand-alone PBMs, ahead of CVS Caremark.

You may also be interested in...



Anthem In-House PBM Will Draw On CVS But Retain Formulary Control

Hybrid approach to pharmacy benefit management expected to save insurer $4bn annually after Anthem ends its relationship with Express Scripts in 2020. Integration of medical and Rx benefit data could lead to more value-based contracting.

Anthem In-House PBM Will Rely On CVS But Retain Formulary Control

Hybrid approach to pharmacy benefit management expected to save insurer $4bn annually after Anthem ends its relationship with Express Scripts in 2020. Plans include "going out to the market and competing with the freestanding PBMs."

Express Scripts-Anthem Split Could Signal Positive Trend For Biopharma

Express Scripts is losing its biggest customer, which could be a sign that plan sponsors are looking for more control over their pharmacy spending -- bad news for the big PBMs but good news for biopharma?

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel